Anthony Boyer, MD
Pulmonary Disease · Richardson, TXNPI 1720240807
Payments from drug & device makers
Across 190 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$601
- AstraZeneca$549
- Boehringer Ingelheim$319
- Sanofi$267
- Mylan Specialty L.p.$158
- plus $1K from 30 others
What the payments were for
- Travel & lodging$5838%
- Food & beverage$3,24046%
- Education$3,01342%
- Gifts$2834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $3,931 |
| GSK | 37 | $601 |
| AstraZeneca | 31 | $549 |
| Boehringer Ingelheim | 18 | $319 |
| Sanofi | 11 | $267 |
| Mylan Specialty L.p. | 9 | $158 |
| Grifols USA, LLC | 5 | $111 |
| Actelion Pharmaceuticals US, Inc. | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Insmed, Inc. | 6 | $97 |
| Electromed, Inc. | 6 | $79 |
| Merck | 5 | $76 |
| Johnson & Johnson | 4 | $74 |
| Mayne Pharma Commercial LLC | 4 | $72 |
| Novartis | 4 | $54 |
| United Therapeutics Corporation | 2 | $53 |
| Shire North American Group Inc | 3 | $51 |
| Portola Pharmaceuticals, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| AbbVie | 2 | $29 |
| Baxter Healthcare | 1 | $27 |
| Genentech USA, Inc. | 2 | $26 |
| Advanced Respiratory, Inc | 2 | $26 |
| Amgen | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $23 |
| Circassia Inc. | 1 | $19 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Organogenesis Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Breathe Technologies, Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,632
How this compares
$7,118 in reported general payments places this provider in the 65th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 392 | $397,766 |
| OfevNintedanib Esylate | 15 | $189,037 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $88,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 100 | $73,975 |
| Dupixent PenDupilumab | 18 | $70,473 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 100 | $68,246 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $50,482 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $49,105 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,174 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $17,572 |
| Arnuity ElliptaFluticasone Furoate | 34 | $10,559 |
| Pirfenidone | 15 | $10,051 |
| EliquisApixaban | 13 | $9,746 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $7,786 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 212 | $6,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $601 | $532,782612 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $319 | $275,457141 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $549 | $74,462118 claims |
| PfizerEliquis | $14 | $9,74613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Richardson
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.